We are live on ! Find out more
MRNA

MARINA BIOTECH INC COM STK (DE)
MRNA

Delisted

MRNA was delisted on the 1st of February, 2012.

2 hedge funds and large institutions have $1.5K invested in MARINA BIOTECH INC COM STK (DE) in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 22 (0)

45% less capital invested

Capital invested by funds: $2.7K → $1.5K (-$1.21K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BAM
Byrne Asset Management
New Jersey
-$1.03K
Name Holding Trade Value Shares
Change
Change in
Stake
BAM
1
Byrne Asset Management
New Jersey
$1.5K -$1.03K -40 -41%

MRNA Hedge Fund Activity: Q3 2025 in Review

2 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in MARINA BIOTECH INC COM STK (DE) (MRNA) for Q3 2025, worth a combined $1.5K — down 45% from $2.7K a quarter earlier.

Fund positioning in MRNA was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Byrne Asset Management, cutting an estimated $1.03K.

  • 2 institutional investors held MARINA BIOTECH INC COM STK (DE) (MRNA) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $1.5K of MARINA BIOTECH INC COM STK (DE) stock for Q3 2025, down 45% quarter-over-quarter.
  • 0 funds opened new MARINA BIOTECH INC COM STK (DE) positions in Q3 2025 and 0 closed out.
  • The largest MARINA BIOTECH INC COM STK (DE) seller in Q3 2025 was Byrne Asset Management, an estimated $1.03K sold.

Based on aggregated 13F filings for Q3 2025.